Version 25
Data Item #3938: ALK Rearrangement

Length: 1
Source of Standard: NAACCR
Section Name: Stage/Prognostic Factors
Year Implemented: 2021
Version Implemented: 21
Record Types: A, M, C, I

XML NAACCR ID: alkRearrangement

Parent XML Element: Tumor

Required Status:

NPCR Collect: . - No recommendations
CoC Collect: RS - Required, site specific
SEER Collect: R - Required
CCCR Collect: . - No recommendations

Description:

Testing for ALK rearrangement is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify tumors which are sensitive to small-molecule ALK kinase inhibitors.

Rationale:

ALK rearrangement is recommended by treatment guidelines for patients with advanced lung cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 01/01/2021+.

Item Data Type:

text

Allowable Values

0-2, 4, 7-9, Blank

Codes:

0	Normal ALK negative Negative for rearrangement, no rearrangement identified, no mutations (somatic) identified, not present, not detected
1	Abnormal Rearrangement identified/detected: EML4-ALK, KIF5B-ALK, TFG-ALK, and/or KLC1-ALK
2	Rearrangement identified/detected: Other ALK Rearrangement not listed in code 1
4	Rearrangement, NOS
7	Test ordered, results not in chart
8	Not applicable: Information not collected for this case If this information is required by your standard setter, use of code 8 may result in an edit error.
9	Not documented in medical record ALK Rearrangement not assessed or unknown if assessed
Blank	Diagnosis year is prior to 2021

Code Notes:

Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.

Version 25 Data Item #3938: ALK Rearrangement